JP2020528447A - 神経変性および炎症性疾患の治療に使用するためのｃｄ３８と特異的に結合する化合物 - Google Patents

神経変性および炎症性疾患の治療に使用するためのｃｄ３８と特異的に結合する化合物 Download PDF

Info

Publication number
JP2020528447A
JP2020528447A JP2020504405A JP2020504405A JP2020528447A JP 2020528447 A JP2020528447 A JP 2020528447A JP 2020504405 A JP2020504405 A JP 2020504405A JP 2020504405 A JP2020504405 A JP 2020504405A JP 2020528447 A JP2020528447 A JP 2020528447A
Authority
JP
Japan
Prior art keywords
disease
antibody
compound
naadp
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020504405A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020528447A5 (OSRAM
Inventor
トゥロルジュ，ダミアン
ダ シルバ，セルヘ ゲレイロ
ダ シルバ，セルヘ ゲレイロ
ブルサック，ローレンス
Original Assignee
エンセファ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エンセファ filed Critical エンセファ
Publication of JP2020528447A publication Critical patent/JP2020528447A/ja
Publication of JP2020528447A5 publication Critical patent/JP2020528447A5/ja
Priority to JP2023114928A priority Critical patent/JP2023134636A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2020504405A 2017-07-24 2018-07-24 神経変性および炎症性疾患の治療に使用するためのｃｄ３８と特異的に結合する化合物 Pending JP2020528447A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023114928A JP2023134636A (ja) 2017-07-24 2023-07-13 神経変性および炎症性疾患の治療に使用するためのｃｄ３８と特異的に結合する化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17315006.1A EP3434692A1 (en) 2017-07-24 2017-07-24 Compounds which specifically binds to cd38 for use in the treatment of neurodegenerative diseases
EP17315006.1 2017-07-24
PCT/EP2018/070064 WO2019020643A1 (en) 2017-07-24 2018-07-24 COMPOUND BINDING SPECIFICALLY TO CD38 FOR USE IN THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY DISEASES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023114928A Division JP2023134636A (ja) 2017-07-24 2023-07-13 神経変性および炎症性疾患の治療に使用するためのｃｄ３８と特異的に結合する化合物

Publications (2)

Publication Number Publication Date
JP2020528447A true JP2020528447A (ja) 2020-09-24
JP2020528447A5 JP2020528447A5 (OSRAM) 2021-09-02

Family

ID=59626538

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020504405A Pending JP2020528447A (ja) 2017-07-24 2018-07-24 神経変性および炎症性疾患の治療に使用するためのｃｄ３８と特異的に結合する化合物
JP2023114928A Pending JP2023134636A (ja) 2017-07-24 2023-07-13 神経変性および炎症性疾患の治療に使用するためのｃｄ３８と特異的に結合する化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023114928A Pending JP2023134636A (ja) 2017-07-24 2023-07-13 神経変性および炎症性疾患の治療に使用するためのｃｄ３８と特異的に結合する化合物

Country Status (7)

Country Link
US (1) US20210087290A1 (OSRAM)
EP (2) EP3434692A1 (OSRAM)
JP (2) JP2020528447A (OSRAM)
CN (1) CN111108127A (OSRAM)
AU (1) AU2018308649A1 (OSRAM)
CA (1) CA3070756A1 (OSRAM)
WO (1) WO2019020643A1 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020205753B2 (en) 2019-01-11 2025-05-29 Omeros Corporation Methods and compositions for treating cancer
US11535621B2 (en) 2019-07-31 2022-12-27 Ribon Therapeutics, Inc. Heterobicyclic amides as inhibitors of CD38
EP4054714A4 (en) * 2019-11-07 2023-12-06 Ohio State Innovation Foundation METHODS AND COMPOSITIONS RELATING TO SELECTIVE INTRACELLULAR DELIVERY OF CD38 INHIBITORS
EP3943505A1 (en) * 2020-07-22 2022-01-26 Encefa Cd38-binding cd31 peptides and uses thereof
WO2022152823A1 (en) 2021-01-14 2022-07-21 Morphosys Ag Anti-cd38 antibodies and their uses
PE20232047A1 (es) 2021-01-29 2023-12-27 Boehringer Ingelheim Int Quinolinas y azaquinolinas como inhibidores de cd38
TW202302642A (zh) 2021-03-01 2023-01-16 德商莫菲西斯公司 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體
JP7782720B2 (ja) 2022-10-28 2025-12-09 日本精工株式会社 回転支持装置、及び軸支持装置の支持機構位置調整機構

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014221761A (ja) * 2006-10-19 2014-11-27 サノフイ 癌の治療のための新規抗ｃｄ３８抗体

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
EP1930342B1 (en) 2006-12-04 2012-01-25 Institut Pasteur OB-fold used as scaffold for engineering new specific binders
JP6093696B2 (ja) * 2010-06-09 2017-03-08 ゲンマブ エー／エス ヒトｃｄ３８に対する抗体
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
US20120328526A1 (en) 2011-06-27 2012-12-27 University Of Maryland, Baltimore Modulation of Nad+ Activity in Neuropathophysiological Conditions and Uses Thereof
WO2015031673A2 (en) 2013-08-28 2015-03-05 Bioasis Technologies Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
WO2016024246A1 (en) 2014-08-14 2016-02-18 Universita' Degli Studi Di Roma 'la Sapienza' A therapeutic use of naadp and/or tcp2 antagonists
BR112017004614A2 (pt) * 2014-09-09 2018-02-27 Janssen Biotech, Inc. terapias de combinação com anticorpos anti-cd38
WO2016210223A1 (en) * 2015-06-24 2016-12-29 Janssen Biotech, Inc. Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38
MY187033A (en) 2015-06-24 2021-08-27 Japan Chem Res Anti-human transferrin receptor antibody permeating blood-brain barrier
US10722529B2 (en) * 2015-12-03 2020-07-28 Temple University—Of the Commonwealth System of Higher Education Modulation of NAD+ metabolic pathways for treatment of disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014221761A (ja) * 2006-10-19 2014-11-27 サノフイ 癌の治療のための新規抗ｃｄ３８抗体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOGERONTOLOGY, vol. 15, JPN6022030432, 2014, pages 177 - 198, ISSN: 0005156660 *
GLIA, vol. 61, no. 1, JPN6022030431, 2013, pages 64 - 65, ISSN: 0005156659 *

Also Published As

Publication number Publication date
AU2018308649A1 (en) 2020-02-13
JP2023134636A (ja) 2023-09-27
EP3658586A1 (en) 2020-06-03
EP3434692A1 (en) 2019-01-30
CA3070756A1 (en) 2019-01-31
CN111108127A (zh) 2020-05-05
US20210087290A1 (en) 2021-03-25
WO2019020643A1 (en) 2019-01-31

Similar Documents

Publication Publication Date Title
JP2020528447A (ja) 神経変性および炎症性疾患の治療に使用するためのｃｄ３８と特異的に結合する化合物
TWI573805B (zh) 抗轉鐵蛋白受體抗體及其使用方法
CN108431041B (zh) 抗siglec-9抗体及其使用方法
JP2022081543A (ja) 抗ｔｒｅｍ２抗体及びその使用方法
CN108137702B (zh) 抗siglec-7抗体及其使用方法
EP3221362B1 (en) Anti-transferrin receptor antibodies and methods of use
KR101245462B1 (ko) Ｓｐ35 항체 및 그의 용도
US20180000964A1 (en) Blood brain barrier receptor antibodies and methods of use
TWI861519B (zh) 抗ctla-4抗體
JP2018518176A (ja) 抗ｃｄ３３抗体及びその使用方法
US20220033520A1 (en) Modified antibody fcs and methods of use
TW200918555A (en) Kit of parts for the treatment of cancer or infectious diseases
US20180222974A1 (en) Compositions and methods for using anti-il-34 antibodies to treat neurological diseases
TWI878289B (zh) 抗ｃｄ３８抗體和調配物
JP2021526794A (ja) 抗Ｓｉｇｌｅｃ−７抗体及びその使用方法
HK40079770A (en) Methods of use of anti-cd33 antibodies
HK1252698B (en) Anti-siglec-9 antibodies and methods of use thereof
HK1243006B (en) Anti-trem2 antibodies and methods of use thereof
HK1243440B (zh) 抗白细胞介素-33抗体及其用途
HK1215584B (zh) 运铁蛋白受体的抗体及其使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210720

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210720

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220726

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221024

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230124

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230713

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230714

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230829

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230929